Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TaiMed Biologics is to take over all manufacturing, developing and commercializing rights from Ambrilia Biopharma for both protease inhibitor (PI) and integrase inhibitor programs for HIV, under an agreement signed between the two parties.
Subscribe to our email newsletter
As per the terms of the agreement, TaiMed is responsible to pay a sum of $250,000 as an upfront payment and might pay up to $7.6m to Ambrilia as a development, regulatory and sales milestone payments.
TaiMed CEO James Chang said TaiMed Biologics has been dedicated to helping patients prevail over HIV since inception and is committed to the ongoing discovery, development and delivery of medicines to fight HIV/AIDS globally.
"We have just completed the phase 2b clinical trial with our lead program, Ibalizumab, a potent entry inhibitor for HIV. The PI and integrase inhibitor programs are welcomed assets as they will bolster and diversify our pipeline," Chang said.